[go: up one dir, main page]

WO2001093844A3 - Compositions pharmaceutiques et utilisation de celles-ci - Google Patents

Compositions pharmaceutiques et utilisation de celles-ci Download PDF

Info

Publication number
WO2001093844A3
WO2001093844A3 PCT/US2001/010824 US0110824W WO0193844A3 WO 2001093844 A3 WO2001093844 A3 WO 2001093844A3 US 0110824 W US0110824 W US 0110824W WO 0193844 A3 WO0193844 A3 WO 0193844A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
serotonin transporter
transporter inhibitor
ht1d antagonist
ht1d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010824
Other languages
English (en)
Other versions
WO2001093844A2 (fr
Inventor
Stephen Nicholas Mitchell
Ian Alexander Pullar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to EP01937165A priority Critical patent/EP1299120A2/fr
Priority to AU2001262928A priority patent/AU2001262928A1/en
Priority to US10/276,107 priority patent/US20030212109A1/en
Publication of WO2001093844A2 publication Critical patent/WO2001093844A2/fr
Publication of WO2001093844A3 publication Critical patent/WO2001093844A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un inhibiteur du transport de sérotonine et un antagoniste 5-HT1D, ainsi qu'un diluant ou excipient pharmaceutiquement acceptable.
PCT/US2001/010824 2000-06-02 2001-05-21 Compositions pharmaceutiques et utilisation de celles-ci Ceased WO2001093844A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01937165A EP1299120A2 (fr) 2000-06-02 2001-05-21 Compositions pharmaceutiques renfermant un inhibiteur du transporteur de la serotonine et utilisation de celles-ci
AU2001262928A AU2001262928A1 (en) 2000-06-02 2001-05-21 Pharmaceutical compositions and their use
US10/276,107 US20030212109A1 (en) 2000-06-02 2001-05-21 Pharmaceutical compositions and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0013503.8 2000-06-02
GB0013503A GB2362826A (en) 2000-06-02 2000-06-02 A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist

Publications (2)

Publication Number Publication Date
WO2001093844A2 WO2001093844A2 (fr) 2001-12-13
WO2001093844A3 true WO2001093844A3 (fr) 2002-04-04

Family

ID=9892909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010824 Ceased WO2001093844A2 (fr) 2000-06-02 2001-05-21 Compositions pharmaceutiques et utilisation de celles-ci

Country Status (4)

Country Link
EP (1) EP1299120A2 (fr)
AU (1) AU2001262928A1 (fr)
GB (1) GB2362826A (fr)
WO (1) WO2001093844A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US8512751B2 (en) 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0701819A2 (fr) * 1994-09-14 1996-03-20 Pfizer Inc. Nouvelles compositions contenant de la sertraline et un agoniste ou antagoniste du récepteur 5-HT1D
EP0780388A1 (fr) * 1995-12-19 1997-06-25 Lilly Industries Limited Des ligands 5HT1Dalpha et 5Ht2A

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
CA2332253A1 (fr) * 1998-05-21 1999-11-25 Eli Lilly And Company Therapie combinee destinee au traitement de la depression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533267A1 (fr) * 1991-09-18 1993-03-24 Glaxo Group Limited Dérivés de benzanilide comme 5-HT1D antagonistes
EP0701819A2 (fr) * 1994-09-14 1996-03-20 Pfizer Inc. Nouvelles compositions contenant de la sertraline et un agoniste ou antagoniste du récepteur 5-HT1D
EP0780388A1 (fr) * 1995-12-19 1997-06-25 Lilly Industries Limited Des ligands 5HT1Dalpha et 5Ht2A

Also Published As

Publication number Publication date
GB2362826A (en) 2001-12-05
GB0013503D0 (en) 2000-07-26
AU2001262928A1 (en) 2001-12-17
WO2001093844A2 (fr) 2001-12-13
EP1299120A2 (fr) 2003-04-09

Similar Documents

Publication Publication Date Title
IL175953A (en) Derivatives of 3-Cycloalkylaminopyrrolidine, their Pharmaceutical Salts and Preparations Containing Them
AU2002236883A1 (en) Microplate storage, transport, and conveyor system
AU2003289440A1 (en) Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
EP1587474A3 (fr) Composes 1, 3-dihydro-isoindolyle a substitution fluoroalcoxy et leurs utilisations pharmaceutiques
AU2001234504A1 (en) Methods, systems, and presentations for delivery over the internet
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
IL168784A (en) Fused 1,3-dihydroimidazole ring compounds and pharmaceutical compositions comprising the same
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
HUP0300541A3 (en) Pharmaceutical compositions for sustained release, containing fluvastatin
ZA200105394B (en) Diphenylurea compounds, a process for their preparation and pharmaceutical composition containing them.
MXPA03003314A (es) Compuestos de c-nitrosoanilina y sus mezclas como inhibidores de polimerizacion.
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
AU2003302653A1 (en) Polymer compound, resist composition and dissolution inhibitor agent containing the polymer compound
ZA200210359B (en) Pharmaceutical compositions.
AU2002211176A1 (en) Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
WO2001093844A3 (fr) Compositions pharmaceutiques et utilisation de celles-ci
NZ516634A (en) Rest-breaking composition for use with deciduous fruit species
WO2006072070A3 (fr) Formulations pharmaceutiques contenant des sels de gallium
GB0001315D0 (en) Organic compounds
MXPA03001557A (es) Derivados bifenilo.
AU2003296168A1 (en) Chuck device of container, transportation device with the same, and chuck claw for the transportation device
HUP0400444A3 (en) Carbapenem compound, pharmaceutical compositions containing them and their use
AU2003271734A1 (en) 7h-dibenzo(b,g)(1,5)dioxocin-5-one derivatives and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10276107

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001937165

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937165

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001937165

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP